Compare Quest Diagnostics Inc (DGX) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.95. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| DGX | SJNK | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.02 | $25.63 |
52-Week Low | $166.42 | $24.75 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SJNK trades at $24.88, down slightly by 0.12% over the past day. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF continues its regular dividend payments, with recent distributions of $0.14 and $0.15 per share. Recent news highlights mixed sentiment, with some analysts cautioning on high-yield bonds while institutional positions see increases.
The outlook for SJNK is clouded by bearish technicals and cautious analyst sentiment, though steady dividends provide income support. Key risks include interest rate sensitivity and credit spread volatility in the high-yield bond market. Investors should weigh the income generation against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
